Biotech Values

[turtlepower]

It looks like Virtex had a P38 program until 2007 and then they shelved it. They too saw QT issues in their trials but nothing significant. They also reported some liver issues but those too weren't significant. The P38 MAPK inhibitors in general appear to have safety issues so the conclusion appears to be that developing them for inflammation will be costly. Given that Virtex was unable to find a partner I doubt ARRY will find one but perhaps they've got a better compound that the Virtex one.